In recent years, the blockade of immune checkpoint molecules with monoclonal antibodies, like those targeting the PD-1/PD-L1 pathway, has enabled the development of breakthrough therapies in oncology, leading to delayed tumor growth and increased survival.
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Non-invasive methods permitting whole-body detection of PD-1 and PD-L1 at high sensitivity and resolution could thus be highly useful in-patient selection and monitoring of PD-1/PD-L1 expression during disease progression and treatment, therefore different approaches have been developed in order to label tumor-specific monoclonal antibodies (Mo)Abs with PET and SPECT radioisotopes. The promising labeling results show an efficient and rapid direct procedure to label (Mo)Abs with Gallim-68 reducing reaction steps and antibody preparation and allowing the future formulation of freeze-dried kit to obtain a PET imaging of PD-1 expressing tumors.
